NasdaqGS:BBIOBiotechs
BridgeBio Pharma (BBIO): Assessing Valuation After Promising Acoramidis Data at AHA and in JAMA Cardiology
BridgeBio Pharma (BBIO) has unveiled fresh clinical results for acoramidis at the American Heart Association Scientific Sessions and in JAMA Cardiology, highlighting significant reductions in all-cause mortality and hospitalization for variant ATTR-CM patients.
See our latest analysis for BridgeBio Pharma.
BridgeBio’s momentum is tough to ignore: shares have surged 137% year-to-date, while the one-year total shareholder return sits at an impressive 199%, fueled in part by headline-making...